J&J partners with Intrexon; Acne drug developer Novan raises $30M;

@FierceBiotech: As trouble mounts, a chastened Martin Shkreli says bad boy persona was just an 'experiment.' Article | Follow @FierceBiotech

@JohnCFierce: Orbimed rings up $950M for biotech Fund VI. Report | Follow @JohnCFierce

@DamianFierce: this is a particularly belabored headline. FDA release | Follow @DamianFierce

> Intrexon ($XON) has struck a collaboration pact with Johnson & Johnson ($JNJ), looking to focus on new therapies that prevent at-risk patients from developing diabetes. Release

> Novan Therapeutics has raised more than $30 million in new funding, according to a new SEC filing. The biotech's lead drug is SB204, which is now in late-stage development for acne, with a Phase III expected to launch in Q1 2016. Filing

> Philadelphia-based Immunome raised $5 million, which will be spent developing new therapeutic antibodies to fight cancer. Release

> Johnson & Johnson backed out of a hepatitis C project with partner Medivir ($MVIR) after charting meager efficacy in Phase I. More (PDF)

> Ionis Pharmaceuticals ($IONS), the former Isis Pharmaceuticals, banked $5 million in its ongoing collaboration with Biogen ($BIIB) after advancing an undisclosed preclinical treatment. News

Medical Device News

@FierceMedDev: ICYMI yesterday: UCLA spinout nabs $10M Series A to diagnose, track traumatic brain injury. Report | Follow @FierceMedDev

@EmilyWFierce: Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story from FiercePharmaMarketing | Follow @EmilyWFierce

> Micro-cap liquid biopsy Dx player Biocept nabs $15M financing from Chicago growth investor. Report

> Olympus played down early report of superbug infections linked to duodenoscope devices. Article

Pharma News

@FiercePharma: Shift in law helps local pharma groups in the Philippines. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: WuXi clarifies just what AstraZeneca is buying, or actually what it isn't buying. Report | Follow @EricPFierce

@CarlyHFierce: Valeant's rep-retention plan worked. Now, its sales folks are 'ready and waiting.' FiercePharmaMarketing story | Follow @CarlyHFierce

> GSK's new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says. Article

> German generics maker mulls $1.1B sale amid pharma's M&A frenzy: Reuters. Report

Pharma Manufacturing News

> Sun said to be discussing $2.3B deal for Intas: DealStreetAsia. Item

> GSK recalls nearly 130,000 Ventolin inhalers. More

> Alnylam looks at building $100M plant outside Cambridge. Story

> Novartis selling French Alcon plant to Recipharm. Article

> Sun says the FDA has issued warning letter for Halol plant. Report

Drug Delivery News

> Antibiotic gel can prevent infection in bone implants. Report

> Eli Lilly partners with Halozyme to develop subcutaneous injectables. News

> FDA approves first chewable extended-release tablet, creating new drug delivery partnership opportunity. More

> J&J's Janssen teams up with Intrexon for diabetes pill. Story

> Startup gets $7M in funding to test its toenail fungus-fighting micro-insert. Article

Pharma Asia News

> Shift in law helps local pharma groups in the Philippines. Item

> Sun Pharma said to be in talks to buy Intas for $2.3B. Story

> 2015 was the year of the (most likely Chinese) health hacker: FT. More

> SciClone Pharmaceuticals sets mucositis treatment for China. Item

> Indian M&A deals top $1.5B in 2015 led by overseas acquisitions. Article

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.